<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04575675</url>
  </required_header>
  <id_info>
    <org_study_id>ChenghsinGH</org_study_id>
    <nct_id>NCT04575675</nct_id>
  </id_info>
  <brief_title>Dapagliflozin on Hypotensive Heart Failure Patients After Sacubitril/Valsartan Therapy</brief_title>
  <official_title>Effects of Dapagliflozin on Hypotensive Patients With Depressed Left Ventricular Ejection Fraction After Sacubitril/Valsartan Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cheng-Hsin General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cheng-Hsin General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The DAPA-HF trial demonstrated that dapagliflozin was able to reduce the risk of worsening&#xD;
      heart failure events and cardiovascular death comparing to placebo in patients with reduced&#xD;
      ejection fraction further to standard of care. However, hypotensive patients who generally&#xD;
      have higher risks comparing to normotensive patients, were under represented in the DAPA-HF.&#xD;
      The investigators aimed to evaluate clinical effects of dapagliflozin on hypotensive heart&#xD;
      failure patients receiving chronic sacubitril/valsartan treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The DAPA-HF trial demonstrated that dapagliflozin was able to reduce the risk of worsening&#xD;
      heart failure (HF) events and cardiovascular death comparing to placebo in patients with&#xD;
      reduced ejection fraction further to standard of care. However, hypotensive patients who&#xD;
      generally have higher risks comparing to normotensive patients, were under represented in the&#xD;
      DAPA-HF. The investigators aimed to evaluate clinical effects of dapagliflozin on hypotensive&#xD;
      HFrEF patients receiving chronic sacubitril/valsartan (Sal/Val) treatment.&#xD;
&#xD;
      This is an investigator-initiated, interventional, prospective. open-label study. The&#xD;
      inclusion criteria were (1) chronic symptomatic HF with New York Heart Association (NYHA)&#xD;
      class II-IV and LVEF less than 40%, (2) treatment with stable and maximal tolerable dose of&#xD;
      Sac/Val, beta-blocker with or without mineralocorticoid receptor antagonist (MRA), (3)&#xD;
      6-minute walking-distance (6MWD)≥ 100meters and ≤425 meters at enrollment, (4) systolic blood&#xD;
      pressure ≤100 mmHg at enrollment. The exclusion criteria were (1) type 1 diabetes mellitus,&#xD;
      (2) patients previously treated with any sodium glucose co-transporter 2 inhibitor (SGLT2i).&#xD;
&#xD;
      After applying the inclusion and exclusion criteria, if the participants had type 2 diabetes&#xD;
      mellitus, the participants will receive dapagliflozin 10mg daily directly. If the&#xD;
      participants did not have history of diabetes mellitus, the participants will be allocated to&#xD;
      either receiving dapagliflozin 10mg daily or receiving standard heart failure treatment&#xD;
      without dapagliflozin.&#xD;
&#xD;
      Vital signs and laboratory tests were examined at baseline, 2-week, 4-week and 12-week.&#xD;
      Six-minute-walking-test, five-level EuroQol five dimensions (EQ-5D-5L) questionnaire and&#xD;
      visual analogue scale (VAS) were collected at baseline and at 12-week.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 29, 2020</start_date>
  <completion_date type="Actual">December 30, 2020</completion_date>
  <primary_completion_date type="Actual">November 25, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>6-minute walking distance</measure>
    <time_frame>12 weeks</time_frame>
    <description>Measuring walking distance within 6 minutes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EQ-5D-5L</measure>
    <time_frame>12 weeks</time_frame>
    <description>Measuring health status. Health status is measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.This version of EQ-5D has five-level scale, The number of levels of severity was classified into: having no problems, having slight problems, having moderate problems, having severe problems and being unable to do/having extreme problems. This version can define 3,125 (5x5x5x5x5) different health states.&#xD;
Valuation of the EQ-5D-5L was then calcuated by the Taiwanese hybrid model, range from -1.0259 to 1. [PLoS One 13(12):e0209344]. Higher score indicates better health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-Visual analogue scale (EQ-VAS)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Evaluating the participants' overall health status. The participant would be asked to mark health status on the day of the interview on a 20 cm vertical scale with end points of 0 and 100. There are notes at the both ends of the scale that the bottom rate (0) corresponds to &quot; the worst health you can imagine&quot;, and the highest rate (100) corresponds to &quot;the best health you can imagine&quot;.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Hypotension</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapagliflozin with standard-of-care therapies for heart failure, including sacubitril/valsartan, beta-blocker, MRA, ICD and CRT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Standard-of-care therapies for heart failure, including sacubitril/valsartan, beta-blocker, MRA, ICD and CRT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>Dapagliflozin 10mg once daily</description>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <other_name>Forxiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sacubitril-Valsartan</intervention_name>
    <description>Sacubitril-Valsartan, maximal tolerated dosage</description>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_label>Standard of care</arm_group_label>
    <other_name>Entresto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beta blocker</intervention_name>
    <description>Cardio-selective beta-blocker, including carvedilol, bisoprolol, metoprolol or nebivolol</description>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_label>Standard of care</arm_group_label>
    <other_name>Concor, Betaloc zok, Nebilet, Carvedilol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mineralocorticoid Receptor Antagonist</intervention_name>
    <description>Mineralocorticoid receptor antagonist, including spironolactone or eplerenone</description>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_label>Standard of care</arm_group_label>
    <other_name>Aldactin, Inspra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cardiac resynchronization therapy and/or implantable cardioverter defibrillator</intervention_name>
    <description>CRT-P, CRT-D or ICD if clinically indicated</description>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_label>Standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  chronic symptomatic HF with New York Heart Association (NYHA) class II-IV and left&#xD;
             ventricular ejection fraction (LVEF) less than 40%&#xD;
&#xD;
          -  treatment with stable and maximal tolerable dose of Sac/Val, beta-blocker with or&#xD;
             without mineralocorticoid receptor antagonist&#xD;
&#xD;
          -  6-minute walking-distance (6MWD)≥ 100meters and ≤425 meters at enrollment&#xD;
&#xD;
          -  systolic blood pressure ≤100 mmHg at enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  hemodialysis&#xD;
&#xD;
          -  severe co-morbidities with life expectancy less than 1 year&#xD;
&#xD;
          -  type 1 diabetes mellitus&#xD;
&#xD;
          -  ever treated with any type of sodium glucose cotransporter 2 inhibitor (SGLT2i)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hung-Yu Chang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cheng-Hsin General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cheng Hsin General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 26, 2020</study_first_submitted>
  <study_first_submitted_qc>September 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cheng-Hsin General Hospital</investigator_affiliation>
    <investigator_full_name>Hung-Yu Chang</investigator_full_name>
    <investigator_title>Attending Physician</investigator_title>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>Dapagliflozin</keyword>
  <keyword>Sacubitril/valsartan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Hypotension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Carvedilol</mesh_term>
    <mesh_term>Sacubitril and valsartan sodium hydrate drug combination</mesh_term>
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
    <mesh_term>Mineralocorticoids</mesh_term>
    <mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

